TGTX
TGTX
NASDAQ · Biotechnology

Tg Therapeutics Inc

$59.83
+1.85 (+3.18%)
As of Nov 7, 1:30 AM ET ·
Financial Highlights (FY 2026)
Revenue
566.41M
Net Income
410.98M
Gross Margin
83.7%
Profit Margin
72.6%
Rev Growth
+504.9%
D/E Ratio
1.10
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 83.7% 67.6% 67.6% 67.6%
Operating Margin 20.0% 11.4% 11.2% 12.8%
Profit Margin 72.6% 12.5% 12.7% 11.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 566.41M 1.04B 1.08B 956.87M
Gross Profit 473.86M 701.79M 727.04M 646.94M
Operating Income 113.34M 118.01M 120.46M 122.04M
Net Income 410.98M 129.57M 136.18M 105.42M
Gross Margin 83.7% 67.6% 67.6% 67.6%
Operating Margin 20.0% 11.4% 11.2% 12.8%
Profit Margin 72.6% 12.5% 12.7% 11.0%
Rev Growth +504.9% +16.6% +24.3% +11.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 2.32B 908.15M 880.79M 975.86M
Total Equity 2.11B 2.79B 2.78B 2.56B
D/E Ratio 1.10 0.33 0.32 0.38
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 113.40M 169.61M 170.48M 149.89M
Free Cash Flow — 110.01M 140.89M 136.27M